Two Japanese pharmaceutical companies refused to test in Russia because of Ukraine

This decision was made by Takeda and Astellas, among other things, due to difficulties with logistics and transactions. Ongoing clinical trials will continue,

Two Japanese pharmaceutical companies - Takeda Pharmaceutical and Astellas Pharma - will refuse to conduct new clinical trials of drugs in RUSSIA, the Nikkei newspaper reports.

According to her, Takeda also stopped all investments in Russian projects. The company's decision was influenced by the problems with logistics and transactions that it faced against the backdrop of sanctions imposed by Western countries against Russia because of Ukraine. Takeda's drug supply and ongoing clinical trials will continue.

Astellas, in turn, will not recruit new patients participating in clinical trials in Russia and Ukraine.

According to Nikkei, Russia and Ukraine occupy a fairly large share of the market for clinical trials, and if the breaks continue long enough, this could affect the schedule for the release of new drugs.

Pharmaceutical companies Bayer and Pfizer suspended investments in Russia Business

On March 14, the Russian division of Takeda announced that it was doing everything necessary for the uninterrupted supply of medicines. At the time of publication, the company's operations in Russia, as well as the work of the plant in Yaroslavl, were carried out as usual.

The company develops medicines in the fields of oncology, gastroenterology, neurology and rare diseases, and also invests in research in areas such as plasma therapy and vaccines.

This crisis is different. What will happen to real estate this time Articles Pro Planning horizon - one day: What will happen to H&M, IKEA and BMW “abandoned” in Russia. Lawyers answer Articles Pro Poorer by billions:

Among others, Takeda manufactures Advate, Human Albumin, Ginipral, Seprotin, Elapraza. In total, the site lists more than 25 items.

Astellas in Russia works in such therapeutic areas as urology, oncology, infectious diseases, gastroenterology and antifungal therapy. The company also produces Prograf, Betanis, Evrenzo.

In mid-March, the German pharmaceutical company Bayer and the American Pfizer suspended investments in Russia. Pfizer has also stopped enrolling patients in ongoing clinical trials, and Bayer has decided to stop all advertising campaigns.

A little later it became known that the American pharmaceutical company Eli Lilly decided to stop the EXPORT of non-essential drugs to Russia. The company explained that the decision will not affect the supply of drugs to combat diabetes, oncology, autoimmune and neurological diseases.

Investment in Russia has also halted pharmaceutical companies MSD and Novartis, and Gilead has decided to halt all non-essential drug business operations in Russia.